Results 81 to 90 of about 1,460,729 (292)

MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. [PDF]

, 2019
Prostate cancer is the most commonly diagnosed cancer in men with African American men disproportionally suffering from the burden of this disease.
Aqeel, Rasha, Cagle, Patrice, Chimeh, Uchechukwu, Collins, Sean P, Dahiya, Rajvir, Kumar, Deepak, Niture, Suryakant, Ramalinga, Malathi, Rios-Colon, Leslimar, Srivastava, Anvesha, Suy, Simeng   +10 more
core   +1 more source

A high-fat diet containing whole walnuts (Juglans regia) reduces tumour size and growth along with plasma insulin-like growth factor 1 in the transgenic adenocarcinoma of the mouse prostate model. [PDF]

, 2012
Prostate cancer (PCa) has been linked to fat intake, but the effects of both different dietary fat levels and types remain inconsistent and incompletely characterised.
Cross, Carroll E, Davis, Paul A, Gohil, Kishorchandra, Khan, Imran H, Kim, Hyunsook, Vasu, Vihas T, Yokoyama, Wallace   +6 more
core   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2019
The original version of this Article contained errors in Fig. 7. In panels e and f, the graph titles incorrectly read ‘LNCaP-AdtNs’ and ‘LAPC4-AdtNs’, respectively. These errors have now been corrected in both the PDF and HTML versions of the Article.
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

Neoplasia: An International Journal for Oncology Research, 2001
BACKGROUND: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%.
Tobias Zellweger, Hideaki Miyake, Laura V. July, Majid Akbari, Satoshi Kiyama, Martin E. Gleave   +5 more
doaj   +1 more source

Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

Frontiers in Psychology, 2020
BackgroundThe psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e ...
Maria Francesca Alvisi, Paola Dordoni, Tiziana Rancati, Barbara Avuzzi, Nicola Nicolai, Fabio Badenchini, Letizia De Luca, Tiziana Magnani, Cristina Marenghi, Julia Menichetti, Villa Silvia, Zollo Fabiana, Salvioni Roberto, Valdagni Riccardo, Valdagni Riccardo, Valdagni Riccardo, Bellardita Lara, the Prostate Cancer Multidisciplinary Clinic Working Group   +17 more
doaj   +1 more source

Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management [PDF]

, 2022
Simona Ferraro, Giacomo Biganzoli, Marco Bussetti, Silvana Castaldi, Elia Biganzoli, Mario Plebani   +5 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Tumor-associated long non-coding RNAs show variable expression across diffuse gliomas and effect on cell growth upon silencing in glioblastoma

Scientific Reports
Long noncoding RNAs (lncRNAs) have been recently recognized as critical components of cancer biology linked to oncogenic processes. Certain lncRNAs are known to act as oncogenes, and the disease-specific expression of many lncRNAs makes them informative ...
Joonas Uusi-Mäkelä, Maria Kauppinen, Janne Seppälä, Serafiina Jaatinen, Birgitta Ryback, Tommi Rantapero, Alejandra Rodriguez-Martinez, Matti Nykter, Kirsi J. Rautajoki   +8 more
doaj   +1 more source

Socio-economic inequalities in survival of patients with prostate cancer: role of age and Gleason grade at diagnosis [PDF]

, 2013
In the United Kingdom, survival of prostate cancer patients has improved since the 1990s. A deprivation gap in survival (better survival for the least deprived compared with the most deprived) has been reported but it is not known if differential ...
Morrison, D., Shafique, M.
core   +2 more sources